Aldarhami Abdu
Department of Medical Microbiology, Qunfudah Faculty of Medicine, Umm Al-Qura University, Al-Qunfudah, Saudi Arabia.
Int J Health Sci (Qassim). 2023 Sep-Oct;17(5):15-22.
Due to the continues emergence of antimicrobial resistance, discovery of novel compounds are urgently required. Thus, this study is focused to identify a novel antimicrobial peptide (bacteriocin) targeting multidrug-resistant pathogenic bacteria.
About 80 environmental isolates were recovered and screened for anti-bacterial activity using simultaneous antagonism assays. Produced peptide (AB3) was purified using Strata-XL-C and Sep-Pack columns. Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) analysis and MIC were conducted on the AB3 peptide to determine its molecular weight and spectrum of activity. Extraction and amplification for the 16S rRNA gene of the producing strain was accomplished using QIAamp DNA Mini Kit and GeneAmp PCR system thermocycler, respectively. Novelty of the compound was assessed based on all obtained genomic and proteomic data using Basic Local Alignment Search Tool search and Unni-Prot and Bactibase, respectively.
About 5% of screened isolates showed antagonistic activity toward tested indicators. Obtained compound showed narrow spectrum of activity toward certain Gram-positive species including, methicillin-sensitive (MSSA), methicillin-resistant (MRSA) and species. MALDI-TOF analysis revealed the flowing molecular masses: 1288.207 Da, 1304.536 Da, 1326.529 Da, 1403.591 Da, and 1472.792 Da. The extensive genomic and proteomic analysis have indicated the discovery of novel bacteriocin produced by .
A novel bacteriocin (AB3) was identified from B. , which has showed promising bactericidal activity toward MSSA, MRSA, and . This compound holds great potential to replace or used in combination with currently used antibiotics to treat serious untreatable bacterial infections. However, further investigations to determine its suitability for therapeutic use in human health are needed.
由于抗菌药物耐药性不断出现，迫切需要发现新的化合物。因此，本研究旨在鉴定一种针对多重耐药病原菌的新型抗菌肽（细菌素）。
收集约80株环境分离株，采用同步拮抗试验筛选其抗菌活性。使用Strata-XL-C柱和Sep-Pack柱纯化产生的肽（AB3）。对AB3肽进行基质辅助激光解吸/电离飞行时间（MALDI-TOF）分析和最低抑菌浓度（MIC）测定，以确定其分子量和活性谱。分别使用QIAamp DNA Mini试剂盒和GeneAmp PCR系统热循环仪完成产生菌株16S rRNA基因的提取和扩增。分别使用基本局部比对搜索工具搜索、Unni-Prot和Bactibase，根据所有获得的基因组和蛋白质组数据评估该化合物的新颖性。
约5%的筛选分离株对测试指标显示出拮抗活性。获得的化合物对某些革兰氏阳性菌表现出窄谱活性，包括甲氧西林敏感金黄色葡萄球菌（MSSA）、耐甲氧西林金黄色葡萄球菌（MRSA）和[此处原文缺失具体菌种]。MALDI-TOF分析显示分子量如下：1288.207 Da、1304.536 Da、1326.529 Da及1403.591 Da和1472.792 Da。广泛的基因组和蛋白质组分析表明发现了由[此处原文缺失具体菌株名称]产生的新型细菌素。
从[此处原文缺失具体菌株名称]中鉴定出一种新型细菌素（AB3），它对MSSA、MRSA和[此处原文缺失具体菌种]显示出有前景的杀菌活性。该化合物在替代或与目前使用的抗生素联合用于治疗严重的难治性细菌感染方面具有巨大潜力。然而，需要进一步研究以确定其在人类健康治疗中的适用性。
